Table 5.
The comparison of the main findings found in this study with previous related reports.
| Author (year) | Analytical platform | Sample type | BCa | RCCa | Controla | Pathways dysregulated in cancer compared to controlb | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Glycolysis | TCA cycle | Fatty acid beta-oxidation | Pentose phosphate pathway | Amino acid metabolism | Lipid metabolism | ||||||
| Cao et al. (44) | NMR | Serum | 37 | 45 | ↑ | ↓ | ↑ | ||||
| Jin et al. (23) | RPLC-MS | Urine | 138 | 121 | ↑ | ↑ | ↑ | ||||
| Wittmann et al. (19) | LC-MS and GC-MS | Urine | 66 | 266 | ↑ | ↑ | * | ↑ | |||
| Zhou et al. (20) | GC-MS | plasma | 92 | 48 | ↑ | ↑ | ↑ | ↑ | |||
| Kim et al. (16) | LC-MS and GC-MS | Urine | 29 | 33 | ↑ | ↑ | ↓ | ||||
| Lin et al. (17) | LC-MS | Serum | 33 | 25 | * | ↓ | * | ||||
| Falegan et al. (18) | NMR and GC-MS | Urine and serum | 40 | 13 | ↑ | ↑ | * | * | |||
| Lin et al. (5) | LC-MS | Serum | 24 | 24 | 24 | * | * | ||||
| Liu et al. (this study) | LC-MS | Serum | 64 | 73 | 141 | * | * | * | * | ||
a
The number of patients recruited in the study.
b
Change trend of the Pathways dysregulated in cancer compared to control. (↑): up-regulated; (↓): down-regulated; (*): dysregulated.